Literature DB >> 12941344

Mapping the kinase domain of Janus Kinase 3.

Christopher Adams1, David J Aldous, Shelley Amendola, Paul Bamborough, Colin Bright, Sarah Crowe, Paul Eastwood, Garry Fenton, Martyn Foster, Trevor K P Harrison, Sue King, Justine Lai, Christopher Lawrence, Jean-Philippe Letallec, Clive McCarthy, Neil Moorcroft, Kenneth Page, Sudha Rao, Jane Redford, Shazia Sadiq, Keith Smith, John E Souness, Sukanthini Thurairatnam, Mark Vine, Barry Wyman.   

Abstract

The utilization and impact of parallel synthesis on lead exploration around initial hit oxindole (1) are described. The emergent SAR, analogue design and functional impact will also be detailed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12941344     DOI： 10.1016/s0960-894x(03)00657-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  14 in total

1.  Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy.

Authors:  Thomas Farkas; Mads Daugaard; Marja Jäättelä
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

2.  Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.

Authors:  Maninder Kaur; Pankaj Kumar Singh; Manjinder Singh; Renu Bahadur; Om Silakari
Journal:  Mol Divers       Date:  2017-11-14       Impact factor: 2.943

3.  Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach.

Authors:  Haneesh Jasuja; Navriti Chadha; Maninder Kaur; Om Silakari
Journal:  Mol Divers       Date:  2014-01-11       Impact factor: 2.943

4.  JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.

Authors:  Naoyuki Nishiya; Yasumitsu Sakamoto; Yusuke Oku; Takamasa Nonaka; Yoshimasa Uehara
Journal:  World J Biol Chem       Date:  2015-11-26

5.  Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.

Authors:  Cornelius Klöck; Xi Jin; Kihang Choi; Chaitan Khosla; Peter B Madrid; Andrew Spencer; Brian C Raimundo; Paul Boardman; Guido Lanza; John H Griffin
Journal:  Bioorg Med Chem Lett       Date:  2010-12-16       Impact factor: 2.823

6.  Development of a high-throughput cell-based reporter assay for screening of JAK3 inhibitors.

Authors:  Chang-Hong Yin; Erika A Bach; Gyeong-Hun Baeg
Journal:  J Biomol Screen       Date:  2011-03-10

7.  IL-2 produced by CD8+ immune T cells can augment their IFN-γ production independently from their proliferation in the secondary response to an intracellular pathogen.

Authors:  Qila Sa; Jerold Woodward; Yasuhiro Suzuki
Journal:  J Immunol       Date:  2013-01-28       Impact factor: 5.422

8.  Late expression of granulysin by microbicidal CD4+ T cells requires PI3K- and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients.

Authors:  Chun Fu Zheng; Gareth J Jones; Meiqing Shi; Jeremy C D Wiseman; Kaleb J Marr; Byron M Berenger; Shaunna M Huston; M John Gill; Alan M Krensky; Paul Kubes; Christopher H Mody
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

9.  Hemagglutinin from the H5N1 virus activates Janus kinase 3 to dysregulate innate immunity.

Authors:  Wei Xu; Minhui Chen; Nanhai Ge; Jun Xu
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

10.  Enzyme kinetics and distinct modulation of the protein kinase N family of kinases by lipid activators and small molecule inhibitors.

Authors:  Matthew D Falk; Wei Liu; Ben Bolaños; Keziban Unsal-Kacmaz; Anke Klippel; Stephan Grant; Alexei Brooun; Sergei Timofeevski
Journal:  Biosci Rep       Date:  2014-04-01       Impact factor: 3.840
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.